Analysis Tools
mortality/aging
|
• all homozygous embryos viable at E18.5 die immediately after birth
|
|
• by E18.5 the number of homozygous embryos is half that expected; however at E15.5 the expected number of homozygous embryos is found
|
cardiovascular system
|
• at E15.5 more than half of the mutant embryos have severely defective angiogenesis
|
cellular
|
• primary mutant MEFs have decreased growth rate with fewer cells in the S- and G2/M phase and more cells in the G1 phase
|
|
• thymocytes from mutant embryos are more susceptible to apoptosis induction
|
|
• more mutant MEFs die spontaneously and treatment with TNFA and anti-tumor agents induces more mutant MEFs to undergo apoptosis compared to wild-type MEFs
|
growth/size/body
|
• at E18.5 viable homozygous embryos are 10-20% smaller by weight compared to control littermates
|
homeostasis/metabolism
liver/biliary system
|
• in mutant embryos the number of hepatocytes and liver weight are reduced however enhanced apoptosis is not seen
|
hematopoietic system
|
• thymocytes from mutant embryos are more susceptible to apoptosis induction
|
immune system
|
• thymocytes from mutant embryos are more susceptible to apoptosis induction
|
endocrine/exocrine glands
|
• thymocytes from mutant embryos are more susceptible to apoptosis induction
|
